Related Experiment Video

Updated: Apr 22, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.2K

Engineered microRNA therapeutics

N W Gibson1

  • 1NW Gibson, Regulus Therapeutics Inc, 3545 John Hopkins Court, San Diego, CA 92121-1121, USA. Email ngibson@regulusrx.com.

The Journal of the Royal College of Physicians of Edinburgh
|October 17, 2014
PubMed

Insights

Engineered microRNA therapeutics offer novel disease treatment strategies by targeting microRNA dysregulation. These approaches, including antimiRs and microRNA mimics, are advancing into clinical trials for various conditions.

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Pharmacology

Background:

  • MicroRNAs (miRNAs) play crucial roles in gene regulation and are implicated in various diseases.
  • Dysregulation of miRNA expression, either overexpression or loss, drives disease progression.
  • Current therapeutic strategies often target individual proteins, missing opportunities to modulate complex disease pathways.

Purpose of the Study:

  • To explore novel therapeutic strategies targeting microRNA dysregulation.
  • To introduce engineered microRNA therapeutics, including antimiRs and miRNA mimics, as potential treatments.
  • To highlight the potential of modulating multiple disease-related proteins via miRNA therapeutics.

Main Methods:

  • Development of chemically modified single-stranded oligonucleotides (antimiRs) to inhibit overexpressed miRNAs.
  • Design of double-stranded nucleic acid molecules (miRNA mimics) to restore lost miRNA expression.
  • Advancement of engineered miRNA therapeutics into clinical development.

Main Results:

  • Engineered miRNA therapeutics demonstrate potential for treating diseases driven by miRNA dysregulation.
  • Human proof-of-concept achieved with an antimiR targeting miR-122, crucial for Hepatitis C virus replication.
  • The approach allows for the modulation of multiple proteins involved in disease pathogenesis.

Conclusions:

  • Engineered microRNA therapeutics represent a paradigm shift in disease treatment.
  • AntimiRs and miRNA mimics offer distinct yet complementary approaches to address miRNA dysregulation.
  • These novel therapeutics hold promise for revolutionizing disease management by targeting complex molecular networks.
Keywords:
anti-miR therapeuticsdeliveryengineered microRNA therapeuticsmicroRNA mimicsoligonucleotides

More Related Videos

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.2K
MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

547

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
20.6K
MicroRNAs01:22

MicroRNAs

9.7K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
24.0K